Biotech Values

[biomaven0]

>ELN

If Tysabri hadn't run into a totally unforeseeable safety problem, the company would have looked very different indeed. So I'd only give this article a "B" rather than an "A" for fairness given he doesn't mention this issue at all.

Drug development is hard, and CNS is harder still, particularly in something like AD. These AD compounds were decent shots on goal and I am happy someone took them (even happier they weren't on my dime, but that's a separate issue).

Peter